EDGAR Filing Documents for 0000950170-23-053875

Form 8-K - Current report:

SEC Accession No. 0000950170-23-053875

Filing Date

2023-10-18

Accepted

2023-10-18 08:04:53

Documents

Period of Report

2023-10-17

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	ovid-20231017.htm iXBRL	8-K	58955
2	EX-99.1	ovid-ex99_1.htm	EX-99.1	39591
	Complete submission text file	0000950170-23-053875.txt		225732

Data Files

Seq	Description	Document	Type	Size
3	XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT	ovid-20231017.xsd	EX-101.SCH	2463
4	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT	ovid-20231017_pre.xml	EX-101.PRE	9839
5	XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT	ovid-20231017_lab.xml	EX-101.LAB	13360
7	EXTRACTED XBRL INSTANCE DOCUMENT	ovid-20231017_htm.xml	XML	4705

Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001

Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381

Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)